πŸ‡ΊπŸ‡Έ FDA
Patent

US 11253604

Conjugate of methotrexate and peptide

granted A61KA61K31/519A61K47/64

Quick answer

US patent 11253604 (Conjugate of methotrexate and peptide) held by CAREGEN CO., LTD. expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CAREGEN CO., LTD.
Grant date
Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/519, A61K47/64, A61K9/0019, A61K9/08